Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
clinical trials
life sciences
national blog main
boston top stories
boston
san francisco blog main
fda
national top stories
cancer
cancer drugs
deals
dyne therapeutics
investing
myotonic dystrophy type 1
rare disease drugs
san diego blog main
third rock ventures
akouos
ally bridge group
amgen
astellas pharma
astellas pharmaceuticals
atlas venture
audentes therapeutics
avidity biosciences
big data analytics
biotech ipos
black diamond therapeutics
blackrock
bladder cancer
bluebird bio
blueprint medicines
california institute for biomedical research
casdin capital
cobimetinib
decibel therapeutics
deciphera pharmaceuticals
diabetic nephropathy
What
drug
6
×
ipo
6
×
medicines
6
×
therapeutics
genetic
biotech
cancer
company
developing
diseases
dyne
lead
million
muscle
new
raised
rare
research
targets
affects
ago
americans
analysis
approved
bio
biotechs
black
bring
brings
clinic
companies
considering
data
date
despite
develop
diamond
disorders
dyne’s
early
Language
unset
6
×
Current search:
drug
×
unset
×
medicines
×
ipo
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds